Janus Kinase Inhibitor
- Name
- Janus Kinase Inhibitor
- Accession Number
- DBCAT003500 (DBCAT005746)
- Description
Agents that inhibit JANUS KINASES.
- ATC Classification
- Drugs
Drug Drug Description Tofacitinib A Janus kinase (JAK) inhibitor used to treat rheumatic conditions, such as rheumatoid arthritis and ankylosing spondylitis, and ulcerative colitis. Baricitinib A Janus kinase inhibitor used to treat moderate to severe rheumatoid arthritis that has responded poorly to at least one TNF antagonist. Abrocitinib A kinase inhibitor used to treat moderate-to-severe atopic dermatitis in adults. Ruxolitinib A kinase inhibitor used to treat various types of myelofibrosis, polycythemia vera in patients who have not responded to or cannot tolerate hydroxyurea, and to treat graft-versus-host disease in cases that are refractory to steroid treatment. Deucravacitinib A TYK2 inhibitor being investigated as a treatment for psoriasis. Pacritinib A kinase inhibitor used for the treatment of primary and secondary myelofibrosis in adult patients with significantly reduced platelet counts. Fedratinib Fedratinib is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.[L8090,L47016] Upadacitinib An oral Janus kinase (JAK)1-selective inhibitor used in the treatment of moderate to severe rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, and severe atopic dermatitis, including in patients who did not respond well to other therapies. - Drugs & Drug Targets